In our study, we found that tumor stromal VEGF-A expression levels were a strong independent predictor of BCSS and DFS in IBC patients; that the tumor stromal VEGF-A level is predictive of DFS, regardless of ER, PR, HER2, and LN status; and that treatment response to tamoxifen (not to aromatase inhibitors) is associated with the tumor stromal VEGF-A expression level. This evidence concerns the gene VEGFA and inflammatory breast carcinoma.